The treatment of occlusive vascular disease with thrombolytic agents opened new perspectives. Whereas platelet mediated reocclusion after myocardial infarction, aprupt closure, and late restenosis after percutaneous transluminal coronary angioplasty (PTCA) remained unresolved despite enormous efforts. As far as the current status of the antiplatelet therapy is concerned, drugs (e.g. ticlopidine) revealed as effective as aspirin. Other promising agents (e.g. ketanserin) failed to become a clinically useful drug. Platelet glycoprotein IIb/IIIa receptor blockers (RGD-peptides and monoclonal antibodies) are currently in the early stages of preclinical and clinical testing and hold promise of preventing reocclusion after recanalisation in myocardial infarction and abrupt closure and late restenosis after PTCA.
|Number of pages||11|
|Publication status||Published - Dec 1 1993|
ASJC Scopus subject areas